Russell Frank Company’s Nektar Therapeutics NKTR Stock Holding History

Russell Frank Company’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$823K	Buy	3,992 +1,573	+65%	+$302K	﹤0.01%	2259
2015 Q4	$622K	Buy	+2,419	New	+$497K	﹤0.01%	2414
2015 Q3	–	Sell	-3,387	Closed	-$636K	–	3036
2015 Q2	$636K	Buy	3,387 +3,274	+2,897%	+$563K	﹤0.01%	2503
2015 Q1	$19K	Sell	113 -7,826	-99%	-$1.61M	﹤0.01%	2899
2014 Q4	$1.83M	Buy	7,939 +3,652	+85%	+$781K	﹤0.01%	1845
2014 Q3	$776K	Buy	4,287 +900	+27%	+$172K	﹤0.01%	2188
2014 Q2	$545K	Buy	+3,387	New	+$599K	﹤0.01%	2299
2013 Q4	–	Sell	-2,302	Closed	-$361K	–	2954
2013 Q3	$361K	Buy	2,302 +667	+41%	+$123K	﹤0.01%	2598
2013 Q2	$283K	Buy	+1,635	New	+$251K	﹤0.01%	2487

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Russell Frank Company's NKTR Position: Q1 2016 in Review

Russell Frank Company increased its Nektar Therapeutics (NKTR) stake by 65% in Q1 2016, buying an estimated $302K and bringing the position to 3,992 shares worth $823K. The position accounts for ﹤0.01% of the portfolio, ranked #2259.

Russell Frank Company first reported a position in NKTR in Q2 2013 and has held it in 9 quarters since. The position peaked at $1.83M in Q4 2014. 176 funds tracked by Wall St. Rank hold NKTR as of Q1 2016.

Russell Frank Company held 3,992 shares of Nektar Therapeutics worth $823K as of Q1 2016.
Russell Frank Company bought 1,573 Nektar Therapeutics shares in Q1 2016, an estimated $302K.
Nektar Therapeutics made up ﹤0.01% of Russell Frank Company's portfolio in Q1 2016, its #2259 holding.
Russell Frank Company first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 9 quarters since.
Russell Frank Company's Nektar Therapeutics position peaked at $1.83M in Q4 2014.
176 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.